摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl (E)-2-(2-nitrobenzylidene)-3-oxobutanoate | 111304-29-1

中文名称
——
中文别名
——
英文名称
methyl (E)-2-(2-nitrobenzylidene)-3-oxobutanoate
英文别名
2-(2-nitrobenzylidene)-acetoacetic acid methyl ester;methyl 2-(2-nitrobenzylidene)-acetoacetate;Methyl 2-(2-nitrobenzylidene)acetoacetate;methyl (2E)-2-[(2-nitrophenyl)methylidene]-3-oxobutanoate
methyl (E)-2-(2-nitrobenzylidene)-3-oxobutanoate化学式
CAS
111304-29-1
化学式
C12H11NO5
mdl
——
分子量
249.223
InChiKey
APKKCRAKPMSAEI-JXMROGBWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    89.2
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • 1,4-dihydropyridine derivatives
    申请人:Fujirebio Inc.
    公开号:US05367081A1
    公开(公告)日:1994-11-22
    1,4-dihydropyridine derivatives and optically active 1,4-dihydropyridine derivatives with the following formula, having vasodilating activity based on calcium antagonism, and PAF antaognism, and methods of producing the same are disclosed: ##STR1## wherein (*) indicates a chiral center in the case of the optically active 1,4-dihydropyridine derivatives.
    1,4-二氢吡啶衍生物和具有以下结构式的光学活性1,4-二氢吡啶衍生物,基于钙拮抗作用具有扩血管活性,以及PAF拮抗作用,以及生产这些物质的方法已被披露:##STR1## 其中(*)表示在光学活性1,4-二氢吡啶衍生物中的手性中心。
  • [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF PURE NISOLDIPINE<br/>[FR] PROCEDE AMELIORE DE PREPARATION DE NISOLDIPINE PURE
    申请人:SANMAR SPECIALITY CHEMICALS LT
    公开号:WO2005023768A1
    公开(公告)日:2005-03-17
    Nisoldipine is prepared by the process according to this invention by cyclocondensing 3-Aminocrotonoic acid isobutyl ester with 2-(2-nitrobenzylidene)-3-oxo-butyric acid methyl ester in the presence of a water immiscible organic solvent such as toluene and an aprotic organic solvent. The reaction product is recovered after refluxing with diisopropyl ether. Water miscible aprotic solvent may be selected from ethers and glycol ethers.
    尼索地平是通过本发明的方法制备的,该方法是通过在水不相容的有机溶剂(如甲苯)和无极性有机溶剂的存在下,将3-氨基巴氨基丙烯酸异丁酯与2-(2-硝基苯甲亚甲基)-3-氧代丁酸甲酯环合反应。在与二异丙基醚回流后,可以回收反应产物。水溶性无极性溶剂可以选择从醚类和乙二醇醚中选取。
  • Sila-substituted 1,4-dihydropyridine derivatives and their medicinal use
    申请人:Bayer Aktiengesellschaft
    公开号:US04237137A1
    公开(公告)日:1980-12-02
    The invention provides sila-substituted 1,4-dihydropyridine derivatives useful as medicament which influence the circulation. Also included in the invention are methods for the procurement of said derivatives, compositions containing said derivatives and methods for the use of said derivatives.
    本发明提供了硅取代的1,4-二氢吡啶衍生物,可用作影响循环的药物。本发明还包括获得所述衍生物的方法,含有所述衍生物的组合物以及使用所述衍生物的方法。
  • ニフェジピンの製造法
    申请人:バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト
    公开号:JP2010065051A
    公开(公告)日:2010-03-25

    PROBLEM TO BE SOLVED: To provide a novel process for producing nifedipine at a high purity in a high yield and in a short reaction time, the process providing nifedipine which should be used directly as an active compound in a medicament with no additional purification operations.

    SOLUTION: The process for producing the nifedipine comprises a step of allowing methyl 2-(2-nitrobenzylidene)acetoacetate to react with methyl 3-aminocrotonate in at least one 2-3C alkanol as a solvent; the reaction is performed at a temperature of 70 to 110°C. The reaction is performed at a temperature preferably of 75 to 95°C, particularly preferably, about 85°C in methanol.

    COPYRIGHT: (C)2010,JPO&INPIT

    需要解决的问题:提供一种新的生产尼群地平的工艺,以高纯度、高产率和短反应时间生产尼群地平,该工艺提供的尼群地平可直接用作药物中的活性化合物,无需进行额外的纯化操作。 解决方案:生产尼群地平的过程包括让甲基2-(2-硝基苯甲醛基)乙酮酸甲酯在至少一种2-3C烷基醇中作为溶剂与甲基3-氨基巴豆酸酯反应的步骤;反应温度为70℃至110℃。反应温度最好为75℃至95℃,特别优选在甲醇中反应时为85℃。 版权所有:(C)2010,JPO&INPIT
  • Process for preparation of substituted dihydropyridines and intermediates therefor
    申请人:USV PHARMACEUTICAL CORPORATION
    公开号:EP0109049A2
    公开(公告)日:1984-05-23
    The invention provides, a new process for preparing dihydropyridines useful in the treatment of hypertension.
    本发明提供了一种用于制备治疗高血压的二氢吡啶类化合物的新工艺。
查看更多